Personalized Antifibrotic Therapy in CKD Progression

Area of Science:

• Nephrology
• Pharmacology
• Genetics

Background:

• Chronic kidney disease (CKD) is marked by kidney fibrosis and extracellular matrix buildup, potentially leading to end-stage renal disease.
• Key pathways like TGF-β, Wnt/β-catenin, Notch, and NF-κB are implicated in fibrosis progression.
• Current treatments, such as renin-angiotensin-aldosterone system inhibitors, only delay CKD progression without reversing fibrosis.

Purpose of the Study:

• To review the critical role of antifibrotic medications in treating chronic kidney disease.
• To emphasize the potential of precision medicine in personalizing CKD treatment strategies.
• To discuss emerging therapeutic targets and drugs for kidney fibrosis.

Main Methods:

• Literature review focusing on molecular pathways, precision medicine approaches, and antifibrotic drug development in CKD.
• Analysis of proteomic signatures (e.g., CKD273) and genetic markers (e.g., APOL1, COL4A5) for patient stratification.
• Examination of preclinical and clinical data for antifibrotic agents like nintedanib, pirfenidone, and investigational drugs targeting CTGF and galectin-3.

Main Results:

• Precision medicine, integrating proteomic, metabolomic, and genetic data, offers a pathway for tailored CKD therapies.
• Proteomic and genetic markers aid in identifying patient subgroups for targeted treatment.
• Nintedanib and pirfenidone have demonstrated antifibrotic effects in preclinical models of kidney disease.

Conclusions:

• There is a significant need for antifibrotic therapies to halt or reverse kidney fibrosis in CKD.
• Personalized treatment approaches leveraging precision medicine are crucial for effective CKD management.
• Investigational drugs targeting specific fibrotic mechanisms show promise for future CKD treatment.